Key result
Chemokines and their receptors play a pivotal role in the pathogenesis of cardiovascular diseases by recruiting immune cells, influencing plaque stability, adverse remodeling, and cardiac dysfunction.
Why the study?
Most attempts to therapeutically target chemokines have been unsuccessful, warranting a better understanding of chemokine-related mechanisms contributing to cardiovascular diseases.
This review highlights the need for a better understanding of chemokine mechanisms in cardiovascular diseases to identify missing gaps and develop successful targeted therapeutics.
Supports chemokine-targeted research in CVD; leaves open which pathways warrant clinical translation.
Cardiovascular diseases (CVD) are increasingly recognized as an outcome of multiple inflammatory processes. Despite a large recent research focus, the majority of attempts to therapeutically target chemokines, have not been successful. Thus, a better understanding of the mechanisms involving chemokines contributing to CVD is warranted to identify the missing gaps in the field. This review summarizes the latest developments on the role of chemokines in the pathogenesis of atherosclerosis, heart failure (HF), coronary artery disease, myocarditis, cardiomyopathy, and arrhythmias. We also aim to provide insight into the current clinical trials and potential therapeutics targeting chemokines and their receptors.
No takes yet. Share an insight, caveat, or question.
Srikanth et al. (2026) conducted a review in Cardiovascular diseases. Chemokines and their receptors play a pivotal role in the pathogenesis of cardiovascular diseases by recruiting immune cells, influencing plaque stability, adverse remodeling, and cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: